1.
患者的临床特征
Clinical characteristics of patients
Category | n (%) |
EGFR: epidermal growth factor receptor; ALK: anaplasticlymphoma kinase. | |
Age (yr) | |
≥60 | 18 (29.0) |
< 60 | 44 (71.0) |
Gender | |
Male | 21 (33.9) |
Female | 41 (66.1) |
Smoking status | |
Ever | 56 (90.3) |
Never | 6 (9.7) |
EGFR mutation | |
Positive | 30 (48.4) |
Negative | 32 (51.6) |
ALK rearrangement | |
Positive | 13 (21.0) |
Negative | 49 (79.0) |
Driver mutation | |
Yes | 43 (69.4) |
No | 19 (30.6) |
Brain metastases | |
Yes | 28 (45.2) |
No | 34 (54.8) |
Bone metastases | |
Yes | 25 (40.3) |
No | 37 (59.7) |
Cycles of bevacizumab | |
≤6 | 32 (51.6) |
> 6 | 30 (48.4) |
Platinum-based regimens | |
Yes | 24 (38.7) |
No | 38 (61.3) |